Savara Inc.

NasdaqGS SVRA

Savara Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Savara Inc. Net Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Savara Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -4,544,500.00%, a -17,111.98% change year over year.
Savara Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -26,403.12%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: SVRA

Savara Inc.

CEO	Mr. Matthew Pauls J.D., M.B.A.
IPO Date	April 28, 2017
Location	United States
Headquarters	Building III
Employees	37
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Key trends

Past 5 years